Ophthalmic device company Quantel Medical said today won a $3.4 million (EU €3 million) contract for ophthalmic laser equipment from India’s Ministry of Defense.
Through the deal, signed by the Directorate General of Armed Forces Medical Services, Quantel Medical is slated to provide 61 photocoagulator lasers for use in 53 military hospitals in India.
“Diabetes is extremely prevalent in India, affecting more than 62 million individuals, or about 7% of the adult population. It is well known that uncontrolled diabetes can be a precursor for the development of vision-related complications, including diabetic retinopathy and diabetic macular edema, both of which are very common in India. One study suggested that as many as 20% of individuals with diabetes in India are affected by diabetic retinopathy,” CEO Jean‐Marc Gendre said in a press release.
The French company said its 532 nm Supra with Suprascan laser platforms are designed to deliver “a number” of Multispot and MicroPulse patterns.
“This agreement will put an extremely powerful treatment option in the hands of physicians who treat patients with diabetic eye disease. It is a platform that can be adapted to use for other applications as well. Laser treatment of diabetes is in many cases as effective as medical treatment, and it is demonstrated to be much more cost effective,” CEO Gendre said in prepared remarks.